Advertisement
This agreement allows Jubilant access to DiscoveRx PathHunter(TM) andcAMPHunter(TM) cell lines and proprietary EFC chemiluminescent detectiontechnology to perform screening on behalf of Jubilant's customers. Theagreement also enables DiscoveRx to expand its platform technology to offerscreening solutions from India.
Advertisement
DiscoveRx's PathHunter(TM) ss-Arrestin and HitHunter(TM) cAMP assays arehomogeneous chemiluminescent assays which are rapidly becoming GPCR screeningplatform of choice for screening and profiling applications. Jubilant'sdemonstrated capabilities in discovery research state of the art medicinalchemistry, modeling, structural biology and screening facilities includingHigh Throughput screening facility supported by automated compound managementand visualization tools coupled with the DiscoveRx award winning assayplatform offers global pharmaceutical companies access to cost effectivescreening and lead generation services that will enable and accelerate globaldrug discovery efforts.
Commenting on the Collaboration, Dr. Kailash Swarna, COO, Global DrugDiscovery, at Jubilant Biosys said:
"We are pleased to announce this agreement with DiscoveRx, and lookforward to the prospect of providing value to our customers using DiscoveRxPathHunter(TM) and HitHunter(TM) technologies. This partnership continues todemonstrate Jubilant's mission to partner with leading technology providersthat provide access to cutting edge and innovative solutions to accelerateglobal drug discovery efforts with our collaborators."
Pyare Khanna, President and CEO, DiscoveRx Corporation says,
"DiscoveRx constantly strives to provide our truly innovative solutionsto screening community. We are determined to help expedite the drug discoveryprocesses and are delighted with this relationship with Jubilant. Ourcustomers require an easy access to our innovative product portfolio and suchpartnerships will add value to our efforts of bringing industry leadingportfolio of PathHunter(TM) and HitHunter(TM) GPCR assays to a broaderaudience."
About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed companyheadquartered in Fremont, California, with an additional office inBirmingham, England. The Company pioneered the use of B-galactosidase enzymefragment complementation in biochemical and cell based assays for discoveryresearch, and holds extensive intellectual property in this area. DiscoveRxis dedicated to the development and commercialization of innovative solutionsto study GPCRs, Kinases and other major drug target classes, and many oftheir innovative products have been widely adopted in pharmaceutical andbiotech drug screening laboratories worldwide. The Company is also arecipient of two Frost and Sullivan 2008 awards: Award for Innovation inNorth American Healthcare Market as well as a European Product Line StrategyAward for it's GPCR Cell Based assay portfolio. For more information onDiscoveRx products, please visit http://www.discoverx.com.
About Jubilant Biosys:
Jubilant Biosys Ltd., a subsidiary of Jubilant Organsys Ltd., providesintegrated drug discovery and development solutions to the globalpharmaceutical industry. Jubilant Biosys has an integrated state of the artfacility in Bangalore. The Center houses over 450 scientists specializing inmultiple disciplines to include Discovery biology, medicinal chemistry,structural biology, pharmacology, toxicology, pharmacy chem., molecularmodeling, crystallography and information technology supporting discoveryefforts. For more information please visit: http://www.jubilantbiosys.comContacts: DiscoveRx Corporation Sailaja Kuchibhatla Sr. VP Business Development DiscoveRx Corp. [email protected] +1-510-979-1415 ext. 104 Jubilant Biosys Ltd. Esha Kakkar Executive - Corporate Planning Jubilant Biosys Ltd. Ph: +91-80-66628683 [email protected]
SOURCE Jubilant Biosys Ltd
